Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18504251 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: bortezomib;   Drug: gemcitabine hydrochloride

Indicates status has not been verified in more than two years